MPL and myeloproliferative neoplasm: TGFB2 was significantly upregulated 3.1-fold in MPL-mutant disease, whereas PTGER3 was downregulated 2.2-fold in MPN lacking JAK2, MPL, or CALR mutations (‘triple negative’ disease).